- Guillain-Barré Syndrome (GBS) is a rare neurological disorder where the body’s immune system attacks the peripheral nerves, often triggered by infections such as Zika virus, influenza, or Campylobacter jejuni
- The market growth is primarily driven by rising incidence of autoimmune and infectious diseases, increased awareness, and advances in early diagnosis and immunotherapy treatments
- North America is expected to dominate the global GBS market owing to high healthcare expenditure, supportive regulatory frameworks, and access to advanced treatment options
- Asia-Pacific is expected to be the fastest growing region in the Guillain-Barré Syndrome (GBS) market during the forecast period due to improving healthcare infrastructure, growing patient awareness, and increasing prevalence of GBS-related infections
- Acute Inflammatory Demyelinating Polyneuropathy (AIDP) segment is expected to dominate the market with a market share of 60.2% due to its high prevalence. AIDP is the most common form of Guillain-Barré Syndrome, characterized by rapid onset muscle weakness caused by damage to the myelin sheath. Early diagnosis and availability of effective treatments such as IVIG and plasmapheresis further support its market dominance
